Is Relay Therapeutics, Inc. (RLAY) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.7% / 30% | 44.2% / 30% | 0.0% / 30% | 347.22% / 5% | ✗ NOT HALAL |
| DJIM | 2.7% / 33% | 44.2% / 33% | 0.0% / 33% | 347.22% / 5% | ✗ NOT HALAL |
| MSCI | 5.6% / 33% | 89.7% / 33% | 0.0% / 33% | 347.22% / 5% | ✗ NOT HALAL |
| S&P | 2.7% / 33% | 44.2% / 33% | 0.0% / 33% | 347.22% / 5% | ✗ NOT HALAL |
| FTSE | 5.6% / 33% | 89.7% / 33% | 0.0% / 50% | 347.22% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -899.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -41.1% | |
| Return on Assets (ROA) | -25.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$235M |
| Free Cash Flow | -$236M |
| Total Debt | $32M |
| Debt-to-Equity | 5.7 |
| Current Ratio | 22.6 |
| Total Assets | $621M |
Price & Trading
| Last Close | $10.12 |
| 50-Day MA | $9.08 |
| 200-Day MA | $6.35 |
| Avg Volume | 2.4M |
| Beta | 1.6 |
|
52-Week Range
$1.77
| |
About Relay Therapeutics, Inc. (RLAY)
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Relay Therapeutics, Inc. (RLAY) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Relay Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Relay Therapeutics, Inc.'s debt ratio?
Relay Therapeutics, Inc.'s debt ratio is 2.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.6%.
What are Relay Therapeutics, Inc.'s key financial metrics?
Relay Therapeutics, Inc. has a market capitalization of $1.7B, and revenue of $15M. Return on equity stands at -41.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.